Tuesday, May 03, 2022 3:53:39 PM
Fluorine rarely occurs naturally in biological molecules, and many compounds containing fluorine are toxic. Fluorine is the most electronegative and reactive of all the elements, and it forms an extremely tight bond with carbon that is difficult for enzymes to break down. This can make it a useful additive for pharmaceutical chemicals, but fluorine's reactivity also makes it a difficult element to work with.
Fluorine is a common element added to pharmaceuticals because it can increase the drug's selectivity, enable it to dissolve in fats, and decrease the speed at which the drug is metabolized, thus allowing it more time to work. Twenty to thirty percent of drugs contain the element, including some of the most widely prescribed drugs such as well-known antibiotics, anti-inflammatories, anti-depressants, cholesterol-lowering medications, and some inhaled anesthetics.
https://phys.org/news/2013-09-method-incorporating-fluoride-drugs.html#:~:text=Fluorine%20is%20a%20common%20element,it%20more%20time%20to%20work.
The way the fluorine works in antibiotics by impairing replication of the mitochondria of the virus. Unfortunately, it seems to cause the same mitochondrial disruption in many of the humans that take these antibiotics.
Recent SINT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/14/2026 12:30:10 PM
- SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution • GlobeNewswire Inc. • 03/23/2026 01:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/20/2026 09:00:53 PM
- SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 01:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 01:00:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:00:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 01:35:38 PM
- SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms • GlobeNewswire Inc. • 02/18/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/11/2026 01:45:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/11/2026 01:44:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/11/2026 01:43:48 AM
- SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5 • GlobeNewswire Inc. • 01/29/2026 02:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/12/2025 05:15:20 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/09/2025 10:01:07 PM
- Sidoti Events, LLC's Year-End Virtual Investor Conference • ACCESS Newswire • 12/09/2025 05:48:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 01:00:05 PM
- SINTX Technologies to Participate in Sidoti & Company Investor Conference • GlobeNewswire Inc. • 12/08/2025 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2025 01:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 01:35:26 PM
- SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants • GlobeNewswire Inc. • 12/01/2025 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 01:05:43 PM
